SCIENTECH (02291) has announced its interim results for the six months ended June 30, 2026, with total operating revenue reaching RMB 310 million, a year-on-year decrease of 5.94%. Net profit attributable to shareholders of the parent company stood at RMB 147 million, reflecting a 19.49% decline compared to the same period last year, while basic earnings per share came in at RMB 0.4226.

The group has established four dedicated marketing teams focused on congenital heart disease, electrophysiology, heart valves, and international trade, continuously expanding its sales channels. By leveraging volume-based procurement initiatives, the company is accelerating market penetration across its product pipelines in the domestic market.

Moving forward, the group aims to strengthen and deepen its collaboration with research institutions, hospitals, clinical practitioners, and industry experts, while consistently gathering clinical feedback and market intelligence. This will enable the company to refine its product design and manufacturing processes, enhance its sales service capabilities, and deliver superior products and more comprehensive service systems to both physicians and patients. In parallel with accelerating penetration across its domestic market pipelines, the group is also expediting the strategic expansion of its overseas business operations.